NME4

Across TCGA pan-cancer cohorts, NME4 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NME4 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NME4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NME4 expression acts as an unfavorable survival marker.

PDAC and GBM are the cancer types where NME4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.352	0.733	.001	45	view →
GBM	DFS	Tertile	All	0.667	0.875	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

NME4–PDAC (OS)

Open the PDAC breakdown →